Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management of Atrial Fibrillation Postoperatively: DAWA Pilot Study

André Rodrigues Durães, Pollianna de Souza Roriz, Bianca de Almeida Nunes, Felipe Pinho E Albuquerque, Fábio Vieira de Bulhões, Andre Mauricio de Souza Fernandes, Roque Aras, André Rodrigues Durães, Pollianna de Souza Roriz, Bianca de Almeida Nunes, Felipe Pinho E Albuquerque, Fábio Vieira de Bulhões, Andre Mauricio de Souza Fernandes, Roque Aras

Abstract

Objectives: Dabigatran is a direct thrombin inhibitor shown to be an effective alternative to warfarin in patients with non-valvular atrial fibrillation (AF). We evaluated the use of dabigatran in patients with bioprosthetic mitral and/or aortic valve replacement and AF.

Methods: We selected 34 and randomized 27 patients in a 1:1 ratio to receive dabigatran or warfarin. The primary endpoint was the presence of a new intracardiac thrombus at 90 days, by transesophageal echocardiogram (TEE). Secondary endpoints included the development of dense spontaneous echo contrast (SEC) and incidence of stroke (ischemic or hemorrhagic), myocardium infarction, valve thrombosis and peripheral embolic events.

Results: The trial was terminated prematurely because of low enrollment. There were 27 patients in total: 15 patients placed in the dabigatran group and 12 in the warfarin group. After 90 days, one patient (8.3 %) in the warfarin group and none in the dabigatran group had developed a new intracardiac thrombus. In the dabigatran group, two patients (13.3 %) developed dense SEC versus one patient (8.3 %) in the warfarin group. In the warfarin group, one patient (8.3 %) presented ischemic stroke, and none did in the dabigatran group. We observed no cases of hemorrhagic stroke, valve thrombosis, embolic events or myocardial infarction in either group throughout the study. However, one patient (6.7 %) in the dabigatran group had a fully recovered transient ischemic attack and one patient in the warfarin group died of heart failure.

Conclusions: The use of dabigatran appears to be similar to warfarin in preventing the formation of intracardiac thrombus.

Trial registration: Clinicaltrials.gov NCT01868243.

References

    1. Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet. 2009;374(9689):565–576. doi: 10.1016/S0140-6736(09)60780-7.
    1. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur J Cardiothorac Surg. 2012;42(4):S1–S44. doi: 10.1093/ejcts/ezs455.
    1. Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet. 2015;S0140–6736(15):60243–60244.
    1. O’Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34(4):894–901. doi: 10.1016/j.clinthera.2012.01.019.
    1. Akwaa F, Spyropoulos AC. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. Curr Med Res Opin. 2014;30(11):2179–2190. doi: 10.1185/03007995.2014.951425.
    1. Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–1214. doi: 10.1056/NEJMoa1300615.
    1. Forsberg P, DeSancho MT. Role of novel anticoagulants for patients with mechanical heart valves. Curr Atheroscler Rep. 2014;16(11):448. doi: 10.1007/s11883-014-0448-7.
    1. Duraes AR, Roriz PD, Bulhoes FV, et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: protocol. JMIR Res Protoc. 2014;3(2):e21. doi: 10.2196/resprot.3014.
    1. Sugioka K, Takagi M, Sakamoto S, et al. Predictors of silent brain infarction on magnetic resonance imaging in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study. Am Heart J. 2015;169(6):783–790. doi: 10.1016/j.ahj.2015.03.016.
    1. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23(4):961–969. doi: 10.1016/0735-1097(94)90644-0.
    1. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694. doi: 10.1111/j.1538-7836.2005.01204.x.
    1. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100. doi: 10.1378/chest.10-0134.
    1. Duraes AR, Duraes MA, Correia LC, et al. Antithrombotic strategy in the three first months following bioprosthetic heart valve implantation. Arq Bras Cardiol. 2013;101(5):466–472.
    1. Iung B, Vahanian A. Lessons from the RE-ALIGN trial. Arch Cardiovasc Dis. 2014;107(5):277–279. doi: 10.1016/j.acvd.2014.02.002.
    1. Ramos AI, Magalhaes AM, Maldonado M, et al. Incidence of intracardiac thrombus and thromboembolism in the first three months after bioprosthetic valve implantation. Arq Bras.Cardiol. 2004;83 Spec No:46–52.
    1. Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk: a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol. 2005;45(11):1807–1812. doi: 10.1016/j.jacc.2004.11.071.
    1. Connolly SJ, Wallentin L, Ezekowitz MD. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013;128(3):237–243. doi: 10.1161/CIRCULATIONAHA.112.001139.
    1. Ruff CT, Giugliano RP, Braunwald E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0.
    1. De Caterina R, Camm AJ. What is ‘valvular’ atrial fibrillation? A reappraisal. Eur Heart J. 2014;35(47):3328–3335. doi: 10.1093/eurheartj/ehu352.
    1. Duraes AR, Duraes Milena AO, Correia LCL, et al. Antithrombotic strategy in the three first months following bioprosthetic heart valve implantation. Arq Bras Cardiol. 2013;101(5):466–472.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren